YTB323

· Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for YTB323, covering 2025-11-20 to 2026-04-06. Get the full timeline:

Most recent: Clinical Trial Update: Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis [Phase 1, Phase 2]

See pricing